MDMA and MDMA-Assisted Therapy
The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
Abstract
MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as "Ecstasy" or "Molly," has been used since the 1970s both in recreational and therapeutic settings. The Food and Drug Administration (FDA) designated MDMA-Assisted Therapy (MDMA-AT) as a Breakthrough Therapy for posttraumatic stress disorder (PTSD) in 2017, and the FDA is requiring an additional phase 3 trial after rejecting the initial New Drug Application in 2024. Unlike other psychedelics, MDMA uniquely induces prosocial subjective effects of heightened trust and self-compassion while maintaining ego functioning as well as cognitive and perceptual lucidity. While recreational use in nonmedical settings may still cause harm, especially due to adulterants or when used without proper precautions, conclusions that can be drawn from studies of recreational use are limited by many confounds. This especially limits the extent to which evidence related to recreational use can be extrapolated to therapeutic use. A considerable body of preliminary evidence suggests that MDMA-AT delivered in a controlled clinical setting is a safe and efficacious treatment for PTSD. After a course of MDMA-AT involving three MDMA administrations supported by psychotherapy, 67%-71% of individuals with PTSD no longer meet diagnostic criteria after MDMA-AT versus 32%-48% with placebo-assisted therapy, and effects endure at long-term follow-up. This review primarily aims to distinguish evidence of recreational use in nonclinical settings versus MDMA-AT using pharmaceutical-grade MDMA in controlled clinical settings. This review further describes the putative neurobiological mechanisms of MDMA underlying its therapeutic effects, the clinical evidence of MDMA-AT, considerations at the level of public health and policy, and future research directions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This neurochemical profile contributes to its prosocial effects, including heightened emotional openness and trust, reduced fear responses, and increased receptivity to social connection, all while generally preserving cognitive clarity and perceptual stability (1).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [1]
In the citing paper
“Emerging research supports the safety and efficacy of psychedelic-assisted therapy (PAT) when administered in a controlled clinical environment (1, 2) for several treatment-resistant psychiatric disorders including depression (3–5), post-traumatic stress disorder (PTSD) (6, 7), substance use disorders (8, 9), social anxiety (10), and obsessive-compulsive disorder (11).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [1]
Citations
Cites
4 retracted
Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05249-5 · Cited by 359
RetractedRicaurte, G. A., Yuan, J., Hatzidimitriou, G., Cord, B. J., & McCann, U. D. (2002) · Science · doi:10.1126/science.1074501 · Cited by 179
RetractedJerome, L., Feduccia, A. A., Wang, J. B., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05548-2 · Cited by 159
RetractedRicaurte, G. A., Yuan, J., Hatzidimitriou, G., Cord, B. J., & McCann, U. D. (2003) · Science · doi:10.1126/science.301.5639.1479b · Cited by 65
RetractedPosttraumatic Stress Disorder in the National Comorbidity Survey
Kessler, R. C. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240066012 · Cited by 10,379
Oxytocin increases trust in humans
Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U., & Fehr, E. (2005) · Nature · doi:10.1038/nature03701 · Cited by 3,690
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Development of a rational scale to assess the harm of drugs of potential misuse
Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60464-4 · Cited by 1,302
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Self-citationPsilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G., M., Garas, W., Paleos, C., Gorman, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01336-3 · Cited by 1,004
Psychotherapy for Military-Related PTSD: A Review of Randomized Clinical Trials
Steenkamp, M. M., Litz, B. T., Hoge, C. W., & Marmar, C. R. (2015) · JAMA · doi:10.1001/jama.2015.8370 · Cited by 958
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Psychometric evaluation of the altered states of consciousness rating scale (OAV)
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012412 · Cited by 683
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378371 · Cited by 674
Rytwinski, N. K., Scur, M. D., Feeny, N. C., & Youngstrom, E. A. (2013) · Journal of Traumatic Stress · doi:10.1002/jts.21814 · Cited by 669
Shulgin, A. T., & Shulgin, A. (1991) · Cited by 668
McCann, U., Szabo, Z., Scheffel, U., Dannals, R., & Ricaurte, G. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04329-3 · Cited by 660
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649
Self-citationPsilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · doi:10.1101/2021.02.17.431629 · Cited by 628
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
Olff, M., Frijling, J. L., Kubzansky, L. D., Bradley, B., Ellenbogen, M. A., Cardoso, C., Bartz, J. A., Yee, J. R., & van Zuiden, M. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.06.019 · Cited by 620
Nichols, D. E. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472362 · Cited by 563
Psychiatric Sequelae of Posttraumatic Stress Disorder in Women
Breslau, N. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130087016 · Cited by 562
A Measure of Interpersonal Dependency
Hirschfeld, R. M. A., Klerman, G. L., Gouch, H. G., Barrett, J., Korchin, S. J., & Chodoff, P. (1977) · Journal of Personality Assessment · doi:10.1207/s15327752jpa4106_6 · Cited by 557
O'Hearn, E., Battaglia, G., De Souza, E., Kuhar, M., & Molliver, M. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-08-02788.1988 · Cited by 542
Jakab, R. L., & Goldman-Rakic, P. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.735 · Cited by 536
Rudnick, G., & Wall, S. C. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1817 · Cited by 535
Ohayon, M. M., & Shapiro, C. M. (2000) · Comprehensive Psychiatry · doi:10.1053/comp.2000.16568 · Cited by 483
MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial
Mitchell, J. M., Ot’alora G., M., van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., Paleos, C., Nicholas, C. R., Quevedo, S., Balliett, B., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02565-4 · Cited by 455
Oxytocin can hinder trust and cooperation in borderline personality disorder
Bartz, J., Simeon, D., Hamilton, H., Kim, S., Crystal, S., Braun, A., Vicens, V., & Hollander, E. (2011) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsq085 · Cited by 452
Vollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00013-x · Cited by 448
Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30135-4 · Cited by 439
Lee, D. J., Schnitzlein, C. W., Wolf, J. P., Vythilingam, M., Rasmusson, A. M., & Hoge, C. W. (2016) · Depression and Anxiety · doi:10.1002/da.22511 · Cited by 416
Subjective Reports of the Effects of MDMA in a Clinical Setting
Greer, G., & Tolbert, R. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472364 · Cited by 413
Recreational MDMA use in Sydney: a profile of ‘Ecstasy’ users and their experiences with the drug
SOLOWIJ, N., HALL, W., & LEE, N. (1992) · British Journal of Addiction · doi:10.1111/j.1360-0443.1992.tb02003.x · Cited by 413
Oehen, P., Traber, R., Widmer, V., & Schnyder, U. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112464827 · Cited by 400
Preller, K. H., Burt, J. B., Ji, J. L., Schleifer, C. H., Adkinson, B. D., Stämpfli, P., Seifritz, E., Repovs, G., Krystal, J. H., Murray, J. D., et al. (2018) · eLife · doi:10.7554/elife.35082 · Cited by 390
Self-citationMithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Martin, S. F., Yazar-Klosinski, B., Michel, Y., Brewerton, T. D., & Doblin, R. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112456611 · Cited by 376
Gender differences in the subjective effects of MDMA
Liechti, M. E., Gamma, A., & Vollenweider, F. X. (2001) · Psychopharmacology · doi:10.1007/s002130000648 · Cited by 360
Psychedelics reopen the social reward learning critical period
Nardou, R., Sawyer, E., Song, Y. J., Wilkinson, M., Padovan-Hernandez, Y., de Deus, J. L., Wright, N., Lama, C., Faltin, S., Goff, L. A., et al. (2023) · Nature · doi:10.1038/s41586-023-06204-3 · Cited by 358
MDMA enhances emotional empathy and prosocial behavior
Hysek, C. M., Schmid, Y., Simmler, L. D., Domes, G., Heinrichs, M., Eisenegger, C., Preller, K. H., Quednow, B. B., & Liechti, M. E. (2014) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nst161 · Cited by 356
Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin
Lebedev, A. V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015) · Human Brain Mapping · doi:10.1002/hbm.22833 · Cited by 339
Hatzidimitriou, G., McCann, U. D., & Ricaurte, G. A. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05096.1999 · Cited by 339
Oxytocin-dependent reopening of a social reward learning critical period with MDMA
Nardou, R., Lewis, E. M., Rothhaas, R., Xu, R., Yang, A., Boyden, E., & Dölen, G. (2019) · Nature · doi:10.1038/s41586-019-1075-9 · Cited by 334
LSD enhances suggestibility in healthy volunteers
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3714-z · Cited by 320
Ricaurte, G. A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410010059035 · Cited by 300
Danforth, A. L., Grob, C. S., Struble, C., Feduccia, A. A., Walker, N., Jerome, L., Yazar-Klosinski, B., & Emerson, A. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5010-9 · Cited by 280
Effects of psilocybin therapy on personality structure
Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart‐Harris, R. L. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12904 · Cited by 267
The harmful health effects of recreational ecstasy: a systematic review of observational evidence
Rogers, G., Elston, J., Garside, R., Roome, C., Taylor, R., Younger, P., Zawada, A., & Somerville, M. (2009) · Health Technology Assessment · doi:10.3310/hta13060 · Cited by 266
Neurotoxicity of MDMA and Related Compounds: Anatomic Studiesa
MOLLIVER, M. E., BERGER, U. V., MAMOUNAS, L. A., MOLLIVER, D. C., O'HEARN, E., & WILSON, M. A. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb16916.x · Cited by 252
Reneman, L., Booij, J., de Bruin, K., Reitsma, J. B., de Wolff, F. A., Gunning, W. B., den Heeten, G. J., & van den Brink, W. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06888-x · Cited by 251
Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression
Murphy, R., Kettner, H., Zeifman, R., Giribaldi, B., Kartner, L., Martell, J., Read, T., Murphy-Beiner, A., Baker-Jones, M., Nutt, D., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.788155 · Cited by 250
A Review of Serotonin Toxicity Data: Implications for the Mechanisms of Antidepressant Drug Action
Gillman, P. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.016 · Cited by 248
Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0569-3 · Cited by 247
Liechti, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00126-3 · Cited by 245
O’Donnell, J., Gladden, R. M., Mattson, C. L., Hunter, C. T., & Davis, N. L. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6935a1 · Cited by 245
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Hartogsohn, I. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00129 · Cited by 229
Ot’alora G, M., Grigsby, J., Poulter, B., Van Derveer, J. W., Giron, S. G., Jerome, L., Feduccia, A. A., Hamilton, S., Yazar-Klosinski, B., Emerson, A., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118806297 · Cited by 226
Berger, U. V., Gu, X. F., & Azmitia, E. C. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90023-w · Cited by 210
Effects of MDMA on sociability and neural response to social threat and social reward
Bedi, G., Phan, K. L., Angstadt, M., & de Wit, H. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1635-z · Cited by 206
Bouso, J. C., Doblin, R., Farré, M., Alcázar, M. Á., & Gómez-Jarabo, G. (2008) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2008.10400637 · Cited by 205
Autonomic dysregulation and the Window of Tolerance model of the effects of complex emotional trauma
Corrigan, F., Fisher, J., & Nutt, D. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109354930 · Cited by 195
The promises and perils of psychedelic pharmacology for psychiatry
McClure-Begley, T. D., & Roth, B. L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00421-7 · Cited by 194
Schnurr, P. P., Chard, K. M., Ruzek, J. I., Chow, B. K., Resick, P. A., Foa, E. B., Marx, B. P., Friedman, M. J., Bovin, M. J., Caudle, K. L., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.36921 · Cited by 185
Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity
Preller, K. H., Duerler, P., Burt, J. B., Ji, J. L., Adkinson, B., Stämpfli, P., Seifritz, E., Repovš, G., Krystal, J. H., Murray, J. D., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.12.027 · Cited by 183
Self-citationFeduccia, A. A., Jerome, L., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00650 · Cited by 172
Wolfson, P. E., Andries, J., Feduccia, A. A., Jerome, L., Wang, J. B., Williams, E., Carlin, S. C., Sola, E., Hamilton, S., Yazar-Klosinski, B., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75706-1 · Cited by 169
McNamee, S., Devenot, N., & Buisson, M. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.0099 · Cited by 168
Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users
Gouzoulis‐Mayfrank, E., Thimm, B., Rezk, M., Hensen, G., & Daumann, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00114-3 · Cited by 160
Wagner, M. T., Mithoefer, M. C., Mithoefer, A. T., MacAulay, R. K., Jerome, L., Yazar-Klosinski, B., & Doblin, R. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117711712 · Cited by 160
KRAKOW, B., MELENDREZ, D., JOHNSTON, L., WARNER, T. D., CLARK, J. O., PACHECO, M., PEDERSEN, B., KOSS, M., HOLLIFIELD, M., & SCHRADER, R. (2002) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-200207000-00004 · Cited by 155
Differential effects of MDMA and methylphenidate on social cognition
Schmid, Y., Hysek, C. M., Simmler, L. D., Crockett, M. J., Quednow, B. B., & Liechti, M. E. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114542454 · Cited by 155
Dafters, R. I. (1995) · Physiology & Behavior · doi:10.1016/0031-9384(95)00136-7 · Cited by 150
Doly, S., Valjent, E., Setola, V., Callebert, J., Hervé, D., Launay, J.-M., & Maroteaux, L. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5723-07.2008 · Cited by 149
Hardman, H. F., Haavik, C. O., & Seevers, M. H. (1973) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(73)80016-x · Cited by 147
Safety pharmacology of acute MDMA administration in healthy subjects
Vizeli, P., & Liechti, M. E. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117691569 · Cited by 145
Rauch, S. A. M., Kim, H. M., Powell, C., Tuerk, P. W., Simon, N. M., Acierno, R., Allard, C. B., Norman, S. B., Venners, M. R., Rothbaum, B. O., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3412 · Cited by 145
Liechti, M. E., & Vollenweider, F. X. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400313 · Cited by 144
Effects of MDMA and intranasal oxytocin on social and emotional processing
Kirkpatrick, M. G., Lee, R., Wardle, M. C., Jacob, S., & de Wit, H. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.12 · Cited by 143
Dimensions of consciousness and the psychedelic state
Bayne, T., & Carter, O. (2018) · Neuroscience of Consciousness · doi:10.1093/nc/niy008 · Cited by 142
Schenk, S., Gittings, D., Johnstone, M., & Daniela, E. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1407-0 · Cited by 137
Schmidt, C. J., Black, C. K., Abbate, G. M., & Taylor, V. L. (1990) · Brain Research · doi:10.1016/0006-8993(90)90813-q · Cited by 131
Plumb, T. R., Peachey, J. T., & Zelman, D. C. (2014) · Psychological Services · doi:10.1037/a0034958 · Cited by 131
Ebert, A., Kolb, M., Heller, J., Edel, M.-A., Roser, P., & Brüne, M. (2013) · Social Neuroscience · doi:10.1080/17470919.2013.807301 · Cited by 129
Sessa, B., Higbed, L., O’Brien, S., Durant, C., Sakal, C., Titheradge, D., Williams, T. M., Rose-Morris, A., Brew-Girard, E., Burrows, S., et al. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121991792 · Cited by 129
Simon, N. M., Connor, K. M., Lang, A. J., Rauch, S., Krulewicz, S., LeBeau, R. T., Davidson, J. R. T., Stein, M. B., Otto, M. W., Foa, E. B., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0309 · Cited by 126
Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms
MacInnes, N., Handley, S. L., & Harding, G. F. A. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500310 · Cited by 120
Daumann, J., Hensen, G., Thimm, B., Rezk, M., Till, B., & Gouzoulis‐Mayfrank, E. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1719-0 · Cited by 117
The early use of MDMA (‘Ecstasy') in Psychotherapy (1977–1985)
Passie, T. (2018) · Drug Science Policy and Law · doi:10.1177/2050324518767442 · Cited by 116
Death following ingestion of MDMA (ecstasy) and moclobemide
Vuori, E., Henry, J. A., Ojanperä, I., Nieminen, R., Savolainen, T., Wahlsten, P., & Jäntti, M. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00292.x · Cited by 113
Possible Association Between 3,4-Methylenedioxymethamphetamine Abuse and Valvular Heart Disease
Droogmans, S., Cosyns, B., D’Haenen, H., Creeten, E., Weytjens, C., Franken, P. R., Scott, B., Schoors, D. F., Kemdem, A., Close, L., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.045 · Cited by 112
Fantegrossi, W. E., Woolverton, W. L., Kilbourn, M. R., Sherman, P. S., Yuan, J., Hatzidimitriou, G., Ricaurte, G. A., Woods, J. H., & Winger, G. D. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300442 · Cited by 111
Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans
Kirkpatrick, M. G., Francis, S. M., Lee, R., de Wit, H., & Jacob, S. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.04.006 · Cited by 106
MDMA alters emotional processing and facilitates positive social interaction
Wardle, M. C., & de Wit, H. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3570-x · Cited by 96
Cognition in Novice Ecstasy Users With Minimal Exposure to Other Drugs: A Prospective Cohort Study
Schilt, T., de Win, M. M. L., Koeter, M., Jager, G., Korf, D. J., van den Brink, W., & Schmand, B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.728 · Cited by 96
Monson, C. M., Wagner, A. C., Mithoefer, A. T., Liebman, R. E., Feduccia, A. A., Jerome, L., Yazar-Klosinski, B., Emerson, A., Doblin, R., & Mithoefer, M. C. (2020) · European Journal of Psychotraumatology · doi:10.1080/20008198.2020.1840123 · Cited by 96
Docherty, J. R., & Green, A. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00722.x · Cited by 91
MDMA and temperature: a review of the thermal effects of 'Ecstasy' in humans.
Parrott, A. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.08.012 · Cited by 91
Multiple toxicity from 3,4-methylenedioxymethamphetamine (“ecstasy”)
Greene, S. L., Dargan, P. I., O’Connor, N., Jones, A. L., & Kerins, M. (2003) · The American Journal of Emergency Medicine · doi:10.1053/ajem.2003.50028 · Cited by 88
Caramanica, K., Brackbill, R. M., Liao, T., & Stellman, S. D. (2014) · Journal of Traumatic Stress · doi:10.1002/jts.21972 · Cited by 87
Milani, R. M., Parrott, A. C., Turner, J. J., & Fox, H. C. (2004) · Addictive Behaviors · doi:10.1016/j.addbeh.2004.02.044 · Cited by 87
Ecstasy (MDMA) and memory function: a meta‐analytic update
Laws, K. R., & Kokkalis, J. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.857 · Cited by 85
Lisdahl, K. M., & Shear, P. K. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.09.003 · Cited by 83
Effects of MDMA on attention to positive social cues and pleasantness of affective touch
Bershad, A. K., Mayo, L. M., Hedger, K. V., McGlone, F. P., Walker, S. C., & de Wit, H. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0402-z · Cited by 80
Silins, E., Copeland, J., & Dillon, P. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701449237 · Cited by 77
Jenkins, M. M., Colvonen, P. J., Norman, S. B., Afari, N., Allard, C. B., & Drummond, S. P. A. (2015) · Sleep · doi:10.5665/sleep.5044 · Cited by 77
Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study
Huizink, A. C., Ferdinand, R. F., van der Ende, J., & Verhulst, F. C. (2006) · BMJ · doi:10.1136/bmj.38743.539398.3a · Cited by 76
Fatal uncertainty: death-rate from use of ecstasy or heroin
Gore, S. M. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02729-4 · Cited by 74
Two Models of Legalization of Psychedelic Substances: Reasons for Concern
Smith, W., & Appelbaum, P. S. (2021) · JAMA · doi:10.1001/jama.2021.12481 · Cited by 73
Oehen, P., & Gasser, P. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.863552 · Cited by 73
Review of deaths related to taking ecstasy, England and Wales, 1997-2000
Schifano, F., Oyefeso, A., Webb, L., Pollard, M., Corkery, J., & Ghodse, A. H. (2003) · BMJ · doi:10.1136/bmj.326.7380.80 · Cited by 71
The Rapid Rise in Investment in Psychedelics—Cart Before the Horse
Phelps, J., Shah, R. N., & Lieberman, J. A. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.3972 · Cited by 70
Wang, Z., & Woolverton, W. L. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0599-5 · Cited by 66
A reliable model of intravenous MDMA self-administration in naïve mice
Trigo, J. M., Panayi, F., Sòria, G., Maldonado, R. J., & Robledo, P. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0229-7 · Cited by 66
Hake, H. S., Davis, J. K. P., Wood, R. R., Tanner, M. K., Loetz, E. C., Sanchez, A., Ostrovskyy, M., Oleson, E. B., Grigsby, J., Doblin, R., et al. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2018.12.007 · Cited by 66
Illingworth, B. J. G., Lewis, D. J., Lambarth, A. T., Stocking, K., Duffy, J. M., Jelen, L. A., & Rucker, J. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120965915 · Cited by 66
The History of Psychedelics in Medicine
Sessa, B. (2016) · Springer eBooks · doi:10.1007/978-3-642-55214-4_96-1 · Cited by 65
Study of the behavioural responses related to the potential addictive properties of MDMA in mice
Robledo, P., Balerio, G. N., Berrendero, F., & Maldonado, R. J. (2004) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-003-0862-9 · Cited by 64
Posttraumatic growth in exposure therapy for PTSD
Hagenaars, M. A., & van Minnen, A. (2010) · Journal of Traumatic Stress · doi:10.1002/jts.20551 · Cited by 63
Effects of MDMA on body temperature in humans
Liechti, M. (2014) · Temperature · doi:10.4161/23328940.2014.955433 · Cited by 62
Takahashi, M., Shirayama, Y., Muneoka, K., Suzuki, M., Sato, K., & Hashimoto, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071964 · Cited by 61
Self-Reported Psychopathology in Polydrug Users
Sumnall, H. R., Wagstaff, G. F., & Cole, J. C. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104040239 · Cited by 61
Psychedelic therapy: a roadmap for wider acceptance and utilization
Marks, M., & Cohen, I. G. (2021) · Nature Medicine · doi:10.1038/s41591-021-01530-3 · Cited by 59
The History of MDMA as an Underground Drug in the United States, 1960–1979
Passie, T., & Benzenhöfer, U. (2016) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1128580 · Cited by 56
Marseille, E., Kahn, J. G., Yazar-Klosinski, B., & Doblin, R. (2020) · PLOS ONE · doi:10.1371/journal.pone.0239997 · Cited by 56
Sessa, B., Sakal, C., O’Brien, S., & Nutt, D. (2019) · BMJ Case Reports · doi:10.1136/bcr-2019-230109 · Cited by 55
Maples-Keller, J. L., Norrholm, S. D., Burton, M., Reiff, C., Coghlan, C., Jovanovic, T., Yasinski, C., Jarboe, K., Rakofsky, J., Rauch, S., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069124 · Cited by 55
A Case of Mao Inhibitor/MDMA Interaction: Agony After Ecstasy
Smilkstein, M. J., Smolinske, S. C., & Rumack, B. H. (1987) · Journal of Toxicology Clinical Toxicology · doi:10.3109/15563658708992620 · Cited by 54
Drug-induced valvular heart disease
Cosyns, B., Droogmans, S., Rosenhek, R., & Lancellotti, P. (2012) · Heart · doi:10.1136/heartjnl-2012-302239 · Cited by 54
Jardim, A. V., Jardim, D. V., Chaves, B. R., Steglich, M., Ot’alora G., M., Mithoefer, M. C., da Silveira, D. X., Tófoli, L. F., Ribeiro, S., Matthews, R., et al. (2021) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-0980 · Cited by 54
MDA-ASSISTED PSYCHOTHERAPY WITH NEUROTIC OUTPATIENTS: A PILOT STUDY
YENSEN, R., DI LEO, F. B., RHEAD, J. C., RICHARDS, W. A., SOSKIN, R. A., TUREK, B., & KURLAND, A. A. (1976) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-197610000-00002 · Cited by 53
Schmid, Y., Vizeli, P., Hysek, C. M., Prestin, K., Meyer zu Schwabedissen, H. E., & Liechti, M. E. (2016) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000231 · Cited by 53
Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies
Studerus, E., Vizeli, P., Harder, S., Ley, L., & Liechti, M. E. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121998322 · Cited by 53
K. Biezonski, D., & S. Meyer, J. (2011) · Current Neuropharmacology · doi:10.2174/157015911795017146 · Cited by 51
Curry, D. W., Young, M. B., Tran, A. N., Daoud, G. E., & Howell, L. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.003 · Cited by 50
Marseille, E., Mitchell, J. M., & Kahn, J. G. (2022) · PLOS ONE · doi:10.1371/journal.pone.0263252 · Cited by 50
Selmi, K. G. D. F. (1995) · British Journal of Neurosurgery · doi:10.1080/02688699550041836 · Cited by 50
(±)-MDMA and its enantiomers: potential therapeutic advantages of R(−)-MDMA
Pitts, E. G., Curry, D. W., Hampshire, K. N., Young, M. B., & Howell, L. L. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4812-5 · Cited by 47
Cavero, I., & Guillon, J. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.12.004 · Cited by 46
Serotonin toxicity involving MDMA (ecstasy) and moclobemide
Pilgrim, J. L., Gerostamoulos, D., Woodford, N. W. F., & Drummer, O. H. (2011) · Forensic Science International · doi:10.1016/j.forsciint.2011.04.008 · Cited by 45
Interpersonal Dependency in Borderline Personality Disorder: Clinical Context and Empirical Evidence
Bornstein, R. F., Becker-Matero, N., Winarick, D. J., & Reichman, A. L. (2010) · Journal of Personality Disorders · doi:10.1521/pedi.2010.24.1.109 · Cited by 45
Passie, T., & Benzenhöfer, U. (2018) · Drug Testing and Analysis · doi:10.1002/dta.2292 · Cited by 44
Posttraumatic Growth After MDMA‐Assisted Psychotherapy for Posttraumatic Stress Disorder
Gorman, I., Belser, A. B., Jerome, L., Hennigan, C., Shechet, B., Hamilton, S., Yazar‐Klosinski, B., Emerson, A., & Feduccia, A. A. (2020) · Journal of Traumatic Stress · doi:10.1002/jts.22479 · Cited by 44
Kamboj, S. K., Kilford, E. J., Minchin, S., Moss, A., Lawn, W., Das, R. K., Falconer, C. J., Gilbert, P., Curran, H. V., & Freeman, T. P. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115587143 · Cited by 43
Ponte, L., Jerome, L., Hamilton, S., Mithoefer, M. C., Yazar‐Klosinski, B. B., Vermetten, E., & Feduccia, A. A. (2021) · Journal of Traumatic Stress · doi:10.1002/jts.22696 · Cited by 43
Studies with psychedelic drugs in human volunteers
Sellers, E. M., Romach, M. K., & Leiderman, D. B. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.029 · Cited by 42
Schmidt, A., Müller, F., Dolder, P. C., Schmid, Y., Zanchi, D., Liechti, M. E., & Borgwardt, S. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx037 · Cited by 41
Sleep Disturbances and Suicidality in Posttraumatic Stress Disorder: An Overview of the Literature
Weber, F. C., Norra, C., & Wetter, T. C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00167 · Cited by 40
Psilocybin and MDMA reduce costly punishment in the Ultimatum Game
Gabay, A. S., Carhart-Harris, R. L., Mazibuko, N., Kempton, M. J., Morrison, P. D., Nutt, D. J., & Mehta, M. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-26656-2 · Cited by 37
Hanson, K. L., & Luciana, M. M. (2009) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390903042361 · Cited by 34
Molla, H. M., Lee, R., Lyubomirsky, S., & de Wit, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-43156-0 · Cited by 33
Banks, M. L., Sprague, J. E., Czoty, P. W., & Nader, M. A. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0932-7 · Cited by 30
Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database
Makunts, T., Jerome, L., Abagyan, R. A., & de Boer, A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.824288 · Cited by 25
Wolfgang, A. S., & Hoge, C. W. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01446-4 · Cited by 25
Self-citationVerbal Memory Impairment in Polydrug Ecstasy Users: A Clinical Perspective
Kuypers, K. P. C., Theunissen, E. L., van Wel, J. H. P., Perna, E. B. D. S. F., Linssen, A. M. W., Sambeth, A., Schultz, B. G., & Ramaekers, J. G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149438 · Cited by 23
Peterson, A. L., Foa, E. B., Blount, T. H., McLean, C. P., Shah, D. V., Young‐McCaughan, S., Litz, B. T., Schobitz, R. P., Castillo, D. T., Rentz, T. O., et al. (2018) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.07.016 · Cited by 23
Regan, A., Margolis, S., de Wit, H., & Lyubomirsky, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258849 · Cited by 22
Modelling the adverse effects associated with ecstasy use
Fisk, J. E., Murphy, P. N., Montgomery, C., & Hadjiefthyvoulou, F. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.03272.x · Cited by 19
The impact of comorbid cannabis and methamphetamine use on mental health among regular ecstasy users
Scott, L. A., Roxburgh, A., Bruno, R., Matthews, A. J., & Burns, L. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.04.012 · Cited by 19
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse
Marchesi, C., Tonna, M., & Maggini, C. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701459828 · Cited by 18
MDMA enhances pleasantness of affective touch
de Wit, H., & Bershad, A. K. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0473-x · Cited by 18
Remembering Molly: Immediate and delayed false memory formation after acute MDMA exposure
Kloft, L., Otgaar, H., Blokland, A., Toennes, S. W., & Ramaekers, J. G. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.01.005 · Cited by 18
Vakde, T., Diaz, M., Uday, K. A., & Duncalf, R. (2014) · Journal of Medical Case Reports · doi:10.1186/1752-1947-8-204 · Cited by 16
Biezonski, D. K., Piper, B. J., Shinday, N. M., Kim, P. J., Ali, S. F., & Meyer, J. S. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.12.024 · Cited by 13
Ecstasy (3,4-Methylenedioxymethamphetamine)-Induced Inappropriate Antidiuretic Hormone Secretion
Farah, R. E., & Farah, R. (2008) · Pediatric Emergency Care · doi:10.1097/pec.0b013e3181850c91 · Cited by 12
Comparison of the effects of abstinence on MDMA and cocaine self-administration in rats
Highgate, Q., & Schenk, S. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5026-1 · Cited by 11
Searchfield, G. D., Poppe, T. N. E. R., Durai, M., Jensen, M., Kennedy, M. A., Maggo, S. D. S., Miller, A. L., Park, J., Russell, B., Shekhawat, G. S., et al. (2019) · International Journal of Neuroscience · doi:10.1080/00207454.2019.1702544 · Cited by 10
Protracted hyperthermia and delayed rhabdomyolysis in ecstasy toxicity
Ghaffari‐Rafi, A., Eum, K. S., Villanueva, J., & Jahanmir, J. (2020) · Medicine · doi:10.1097/md.0000000000021842 · Cited by 9
Research works printed but not linked: 18
- Greer G, 1985, Advances, 2, 57
- Young FL, 1986, In the Matter of MDMA Scheduling, Docket No 84-48, Opinion and Recommended Ruling, Findings of Fact, Conclusions of Law and Decision of Administrative Law Judge on Issues Two through Seven
- 10.1038/sj.npp.1395197 · DOI · Paper page
- Connolly E, 1999, Crit Care Resusc, 1, 368
- Battaglia G, 1987, J Pharmacol Exp Ther, 242, 911
- Vollenweider F, 2000, Effects of MDMA on 5-HT uptake sites using PET and [11C]-McN5652 in humans
- Stolaroff M, 2004, The Secret Chief Revealed: Conversations with Leo Zeff
- Multidisciplinary Association for Psychedelic Studies, 2021, MDMA Investigator’s Brochure (MDMA)
- Baggott MJ, 2016, Adv Pharmacol Sci, 2016, 2175896
- Mas M, 1999, J Pharmacol Exp Ther, 290, 136
- Baggott M, Jerome L, Stuart R: 3,4-methylenedioxymethamphetamine (MDMA): a review of the english-language scientific and medical literature 2001
- Parrott AC, 2000, Drug Alcohol Depend, 60, 105
- Potash MN, 2009, Psychiatry (Edgmont), 6, 40
- Volpi-Abadie J, 2013, Ochsner J, 13, 533
- Malberg JE, 1996, J Pharmacol Exp Ther, 278, 258
- Adamson S, 2012, Through the Gateway of the Heart: Accounts and Experiences with MDMA and Other Empathogenic Substances
- VA/DoD Clinical Practice Guidelines, 2023, Management of Posttraumatic Stress Disorder and Acute Stress Disorder
- Itzhaky L, 2014, J depress anxiety, 3, 1
Cited by
Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design
Muthukumaraswamy, S. D., Baggott, M. J., Schenberg, E. E., Repantis, D., Wolff, M., Forsyth, A., & Noorani, T. N. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251381074 · Cited by 25
Malhi, G. S., Bell, E., Stavdal, A., Wu, C., Naylor, A., & Kumari, V. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00201-1 · Cited by 23
Askariyan, K., Joghataei, M. T., Dehghan, S., Nohesara, S., Rihipour, L., Mohammadi, M. H., & Ahmadirad, N. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111461 · Cited by 15
Pharmacological Monotherapy for Depressive Disorders: Current and Future—A Narrative Review
Gao, K., Oruc, E. B., & Koparal, B. (2025) · Medicina · doi:10.3390/medicina61040558 · Cited by 14
Nadeem, Z., Parker, S., McGovern, H. T., Sebben, B., & Oestreich, L. (2025) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251346679 · Cited by 10
Metadata
- Authors
- Wolfgang, A. S., Fonzo, G. A., Gray, J. C., Krystal, J. H., Grzenda, A., Widge, A. S., Kraguljac, N. V., McDonald, W. M., Rodriguez, C. I., & Nemeroff, C. B.
- Affiliations
- University of Minnesota (US)
- Directorate of Behavioral Health, Walter Reed National Military Medical Center, Bethesda, MD (Wolfgang); Departments of Psychiatry (Wolfgang) and Medical and Clinical Psychology (Gray), Uniformed Services University, Bethesda, MD; Departments of Psychiatry (Wolfgang, Krystal), Neuroscience (Krystal), and Psychology (Krystal), Yale University School of Medicine, New Haven, CT; Center for Psychedelic Research and Therapy, Department of Psychiatry and Behavioral Sciences, The University of Texas at Austin...
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2025-01-01
- Volume
- 182
- Issue
- 1
- Pages
- 79-103
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W4405977949
- Cited by
- 62
- References
- 169
- Citations by year
- 2026: 34 · 2025: 27
- FWCI
- 13.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- MDMA, MDMA-assisted psychotherapy, ecstasy, post-traumatic stress disorder, psychedelic therapy, recreational drug use, drug adulteration, prosocial effects, neurobiological mechanisms, treatment efficacy, public health policy
- MeSH terms
- Hallucinogens, Humans, Psychotherapy, Stress Disorders, Post-Traumatic, N-Methyl-3,4-methylenedioxyamphetamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.